Table 2.
Comparison of characteristics between progression and non-progression patients during the follow-up
|
Characteristics |
Remission patients |
Non-progression patients |
Progression patients |
P-value |
|---|---|---|---|---|
| (n = 369) | (n = 308) | (n = 61) | ||
| ALB g/L at month 3 |
40.9 ± 4.9 |
41.3 ± 0.6 |
39.0 ± 1.7 |
NS |
| ALB g/L at month 6 |
42.9 ± 4.2 |
43.5 ± 0.6 |
40.5 ± 1.3 |
0.02 |
| TA-ALB g/L |
42.1 ± 3.8 |
42.7 ± 0.5 |
39.4 ± 1.2 |
0.01 |
| SCr μmol/L at month 3 |
90.2 ± 35.5 |
82.7 ± 3.9 |
121.6 ± 13.9 |
0.01 |
| SCr μmol/L at month 6 |
88.2 ± 37.5 |
80.3 ± 4.2 |
121.3 ± 14.1 |
0.002 |
| TA-SCr μmol/L |
91.8 ± 46.8 |
80.5 ± 4.2 |
136.7 ± 21.0 |
0.002 |
| BUN mmol/L at month 3 |
7.4 ± 2.9 |
6.8 ± 0.3 |
9.8 ± 1.1 |
0.01 |
| BUN mmol/L at month 6 |
6.5 ± 2.3 |
6.1 ± 0.3 |
8.0 ± 0.9 |
0.02 |
| TA-BUN mmol/L |
6.6 ± 2.2 |
6.1 ± 0.2 |
8.6 ± 0.9 |
0.004 |
| eGFR (ml/min/1.73 m2) at month 3 |
85.5 ± 33.1 |
90.8 ± 4.4 |
63.4 ± 8.2 |
0.01 |
| eGFR (ml/min/1.73 m2) at month 6 |
88.9 ± 33.7 |
95.1 ± 4.6 |
63.1 ± 7.8 |
0.003 |
| TA-eGFR (ml/min/1.73 m2) |
88.5 ± 33.2 |
95.1 ± 4.5 |
61.9 ± 8.1 |
0.002 |
| UPE (g/d) at month 3 |
0.7 (0.4-1.3) |
0.6 (0.2-1.0) |
1.3 (0.7-2.0) |
0.04 |
| UPE (g/d) at month 6 |
0.4 (0.2-0.7) |
0.4 (0.1-0.7) |
0.4 (0.2-1.2) |
NS |
| TA-UPE (g/d) | 1.1 (0.6-1.6) | 1.0 (0.6-1.4) | 1.3 (1.0-2.1) | NS |
Values are given as means ± standard deviation (SD) if the variables had a normal distribution and as medians (IQR) if the variables did not have a normal distribution; n (%) was used for the categorical variables.
TA-ALB: time-averaged serum albumin; TA-SCr: time-averaged serum creatinine; TA-BUN: time-averaged blood urea nitrogen; TA-eGFR: time-averaged eGFR; TA-UPE: time-averaged 24-h urinary protein excretion.